RxDoctor Payments Data

Akkil Ali, MD

Internal Medicine · Tamarac, FLNPI 1902991367

Payments from drug & device makers

$435in general payments, 2019–2025

Across 23 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$135
  • Amgen$104
  • Novartis$85
  • Pfizer$48
  • Bayer$20
  • Eisai Inc.$19
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$435 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$201,248
Medicare patients
234
Services billed
2,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin332$128,511
EliquisApixaban333$112,983
ProcritEpoetin Alfa62$42,663
JanuviaSitagliptin Phosphate93$34,252
TrulicityDulaglutide32$25,849
MounjaroTirzepatide21$23,333
XifaxanRifaximin14$22,738
XareltoRivaroxaban37$17,200
Synjardy XrEmpagliflozin/Metformin Hcl37$17,167
FarxigaDapagliflozin Propanediol33$16,805
EntrestoSacubitril/Valsartan29$15,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$11,770
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$10,970
ErtapenemErtapenem Sodium25$10,435
Fiasp FlextouchInsulin Aspart (Niacinamide)52$9,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$48$116,992368 claims
Lilly USA, LLCTrulicity, Mounjaro$135$49,18253 claims
NovartisEntresto$85$15,25029 claims
AmgenEpogen$104$9,40641 claims
BayerKerendia$20$7,60523 claims
Novo NordiskFiasp$12$3,76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →